Malz Ronny, Weithauser Alice, Tschöpe Carsten, Schultheiss Heinz-Peter, Rauch Ursula
Centrum für Herz- und Kreislaufmedizin, Medizinische Klinik II, Charité - Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany.
Cardiovasc Ther. 2014 Jun;32(3):113-9. doi: 10.1111/1755-5922.12069.
Myocarditis is induced by coxsackievirus B3 (CVB3). Myocardial inflammation is tied to the activation of coagulation. Coagulation factor (F) Xa, a central player in coagulation, activates matrix metalloproteinases (MMP), which modulate the remodeling.
In this study, we investigated the effects of pharmacological FXa inhibition on myocardial function, inflammation, and remodeling during a CVB3-induced myocarditis.
Immune cells and matrix proteins were detected by immunohistochemistry. The expression of cytokines was measured by real-time PCR and the activity of MMP-2 by zymography. Left ventricular function was analyzed using microconductance pressure catheter. Treatment with the FXa inhibitor fondaparinux led to an improved left ventricular function in CVB3-induced mice compared to saline-treated controls (dPdtmax: fondaparinux 4632 ± 499.6 vs. saline 3131 ± 374.0 [mmHg/s], P = 0.0503; SV: fondaparinux 33.19 ± 4.893 vs. saline 19.32 ± 2.236 [μL], P < 0.118; CO: fondaparinux 15124 ± 2183 vs. saline 8088 ± 1035 [μL/min], P < 0.05). Therapy with fondaparinux reduced the activity of MMP-2 (fondaparinux 1.208 ± 0.1247 vs. saline 1.565 ± 0.05476, P < 0.05). The collagen type I/III ratio as well as the expression of TIMP-1 was comparable in both infection groups postinfectionem (p.i.), despite an increased infiltration of macrophages into the hearts of mice treated with fondaparinux 8 days p.i. (CD68+: fondaparinux 494.2 ± 64.73 vs. saline 306.9 ± 43.73 [cells/mm(2) ], P < 0.05). Anti-inflammatory CD206-positive M2-type macrophages were increased in the infected hearts after fondaparinux treatment (CD206+: fondaparinux 182.1 ± 18.18 vs. saline 111.6 ± 21.07 [cells/mm(2) ], P < 0.05), whereas CD80-positive M1-type macrophages were comparable in both groups.
In conclusion, selective inhibition of FXa improves the left ventricular function during CVB3-induced myocarditis and seems to be associated with an improved myocardial remodeling.
柯萨奇病毒B3(CVB3)可诱发心肌炎。心肌炎症与凝血激活有关。凝血因子(F)Xa是凝血过程中的关键因子,可激活基质金属蛋白酶(MMP),后者参与调节心肌重塑。
在本研究中,我们探究了药物性抑制FXa对CVB3诱发心肌炎期间心肌功能、炎症及重塑的影响。
通过免疫组织化学检测免疫细胞和基质蛋白。采用实时聚合酶链反应测定细胞因子表达,用酶谱法检测MMP-2活性。使用微电导压力导管分析左心室功能。与生理盐水处理的对照组相比,用FXa抑制剂磺达肝癸钠治疗可改善CVB3诱发小鼠的左心室功能(dPdtmax:磺达肝癸钠4632±499.6 vs.生理盐水3131±374.0[mmHg/s],P = 0.0503;SV:磺达肝癸钠33.19±4.893 vs.生理盐水19.32±2.236[μL],P < 0.118;CO:磺达肝癸钠15124±2183 vs.生理盐水8088±1035[μL/min],P < 0.05)。磺达肝癸钠治疗降低了MMP-2活性(磺达肝癸钠1.208±0.1247 vs.生理盐水1.565±0.05476,P < 0.05)。尽管感染后8天用磺达肝癸钠治疗的小鼠心脏中巨噬细胞浸润增加(CD68+:磺达肝癸钠494.2±64.73 vs.生理盐水306.9±43.73[细胞/mm²],P < 0.05),但感染后两组的I/III型胶原比例以及TIMP-1表达相当。磺达肝癸钠治疗后感染心脏中抗炎性CD206阳性M2型巨噬细胞增加(CD206+:磺达肝癸钠182.1±18.18 vs.生理盐水111.6±21.07[细胞/mm²],P < 0.05),而两组中CD80阳性M1型巨噬细胞相当。
总之,选择性抑制FXa可改善CVB3诱发心肌炎期间的左心室功能,且似乎与改善心肌重塑有关。